PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 23 filers reported holding PHARVARIS N V in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $703,256 | +2.5% | 33,697 | -25.7% | 0.00% | – |
| Q2 2023 | $686,327 | +73.9% | 45,332 | -7.5% | 0.00% | – |
| Q1 2023 | $394,574 | -8.1% | 48,985 | +28.3% | 0.00% | – |
| Q4 2022 | $429,525 | +194.2% | 38,180 | +99.9% | 0.00% | – |
| Q3 2022 | $146,000 | -60.8% | 19,095 | +13.6% | 0.00% | – |
| Q2 2022 | $372,000 | +26.5% | 16,816 | +3.9% | 0.00% | – |
| Q1 2022 | $294,000 | +12.2% | 16,185 | -11.3% | 0.00% | – |
| Q4 2021 | $262,000 | -15.8% | 18,256 | +4.0% | 0.00% | – |
| Q3 2021 | $311,000 | -16.4% | 17,547 | -12.2% | 0.00% | – |
| Q2 2021 | $372,000 | +175.6% | 19,984 | +313.3% | 0.00% | – |
| Q1 2021 | $135,000 | – | 4,835 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |